Teva Pharmaceutical Industries Ltd (NYSE and TASE: TEVA) launched LongActingImpact.com on Sept. 16, 2026, an educational resource for healthcare providers focused on long-acting injectables for schizophrenia.

The website aims to equip clinicians with evidence-based information to support informed treatment discussions and decision-making regarding long-acting injectables (LAIs). Teva stated the resource is designed to help remove systemic hurdles and complexities that often create barriers to care.

Adherence Challenges

According to an analysis cited by the company, 67% of patients taking oral medications for schizophrenia were nonadherent or stopped taking them altogether. Despite this high rate of discontinuation, LAIs remain underutilized due to perceived patient resistance and operational complexities.

The new resource provides healthcare providers with information on key topics, including:

• How LAIs reduce relapse risk and protect patient outcomes
• Strategies for ensuring consistent treatment delivery when patients struggle with adherence to daily medication
• How LAIs can support continuity of care during the transition from inpatient to outpatient settings
• Step-by-step guidance for navigating patient conversations, from identifying life goals to building trust

Market Context

An estimated 2.2 million people are currently diagnosed with schizophrenia in the U.S. The condition is linked to suboptimal long-term outcomes, with medication adherence frequently presenting as a major impediment to effective care.

Verena Ramirez Campos, VP of U.S. Medical Affairs and Global Innovative Strategy at Teva, noted that long-acting injectables can help address consistent medication adherence but their potential cannot be fully realized if they are not considered as a treatment option.

Bryce Reynolds, MD at Carolina Outreach, added that many patients do not hear about long-acting injectables until after they have experienced repeated relapses or hospitalizations, even though they have been part of schizophrenia care for years.

What the Numbers Show

The data highlights a significant gap between clinical need and treatment adoption. While 67% of oral medication patients exhibit nonadherence or discontinuation, LAIs remain underutilized. This divergence suggests that barriers to adoption are likely procedural or educational rather than purely clinical efficacy issues, as evidenced by Teva’s focus on providing “practical guidance” and “step-by-step” conversation tools rather than just efficacy data.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced the launch of an offering for senior notes through its special purpose finance subsidiaries. The company intends to issue both Euro-denominated and USD-denominated notes to refinance outstanding obligations.

The offering is subject to market conditions. Teva expects to use the net proceeds, along with cash on hand, for three primary purposes. First, the funds will finance the conditional redemptions of specific existing notes. Second, they will cover fees and expenses related to the transaction. Third, any remaining proceeds will be used for general corporate purposes, including repaying outstanding debt upon maturity or earlier redemption.

Conditional Redemptions

In connection with the offering, Teva intends to issue notices of conditional redemption. These redemptions are conditioned on the consummation of the new notes offering, although the offering itself is not conditioned on the redemptions. The company plans to redeem the following instruments:

Teva retains the discretion to issue additional notices of conditional redemption or amend the principal amounts to be redeemed, in accordance with the relevant indentures.

Structure and Guarantees

The new notes will be unsecured senior obligations of the issuers. They will be unconditionally guaranteed on a senior basis by Teva Pharmaceutical Industries Ltd. The issuance will be made pursuant to an effective automatic shelf registration statement on Form S-3, filed with the Securities and Exchange Commission on February 7, 2025.

Net proceeds from the offering may be temporarily invested pending their application for the stated purposes. The offering involves multiple financial institutions, including BNP Paribas, Citigroup, Goldman Sachs, and J.P. Morgan, acting as syndicate agents.